AAS
BTAI icon

Ameritas Advisory Services’s BioXcel Therapeutics BTAI Stock Holding History

Ameritas Advisory Services’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6
Closed -$1.87K – 806
2023
Q1 		$1.87K Buy
+6
New +$2.56K ﹤0.01% 2406

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ameritas Advisory Services's BTAI Position: Q2 2023 in Review

Ameritas Advisory Services sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 6 shares — an estimated $1.87K sold.

Ameritas Advisory Services first reported a position in BTAI in Q1 2023 and held it in 1 quarter. The position peaked at $1.87K in Q1 2023. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

  • Ameritas Advisory Services reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ameritas Advisory Services sold 6 BioXcel Therapeutics shares in Q2 2023, an estimated $1.87K.
  • Ameritas Advisory Services first reported a position in BioXcel Therapeutics in Q1 2023 and held it in 1 quarter.
  • Ameritas Advisory Services's BioXcel Therapeutics position peaked at $1.87K in Q1 2023.
  • 88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on Ameritas Advisory Services's 13F filing for Q2 2023, filed 25 Jul 2023.